Friday, January 22, 2010
Vermillion Emerges From Bankruptcy -- FREMONT, Calif., Jan. 22 /PRNewswire-FirstCall/ --
"This is a great day for all of our stakeholders as well as women who will benefit from OVA1,' said Gail Page, executive chair of Vermillion. 'We are in a position to resume development of our other programs in ovarian cancer and peripheral arterial disease,' she added."
full free access: Progress in Cancer Care: A Rational Call To Do Better - CA: A Cancer Journal for Clinicians
Editorial by incoming American Cancer Society President - Dr Alan G. Thorson
Study Finds Omission of Axillary Lymph Node Dissection Safe for Patients with Sentinel Node Micrometastases (early stage breast cancer)
full free access: link: http://caonline.amcancersoc.org/cgi/reprint/60/1/2.pdf
BRCA1 185delAG mutant protein, BRAt, up-regulates Maspin in ovarian epithelial cells
"Consequently, understanding early genotypic and phenotypic changes in the context of high risk disease may provide a better understanding of the mechanism of mutation-associated ovarian cancer and provide new targets for therapeutic intervention."
Maintenance immunotherapy in recurrent ovarian cancer: Long term follow-up of a phase II study
"Therapy consisted of low-dose subcutaneous IL-2 and oral RA, administered on intermittent schedules for up to 5 years."
Trial design for evaluation of novel targeted therapies
"Conclusions:Alternatives to traditional phase II trial design including alternative end points, randomized designs, biomarkers, and imaging tools should allow ineffective agents to be discarded and promising agents to undergo further investigation."
Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma
"Conclusion: Gefitinib, administered in combination with paclitaxel and carboplatin, provides a good clinical response but associated with an increased risk of hematologic disorders."
Nurses oppose the Ontario government's physician assistant role citing inadequate education, concerns over patient safety and unnecessary cost
Note: the RNAO also made the same statement regarding pharmacists (2009)
Toronto, January 22, 2010
"Members of the public will not be well served if the provincial government pursues a plan to allow physician assistants (PAs) to work in hospitals, family health teams, community health centres, and family physician offices. The board of directors of the Registered Nurses' Association of Ontario (RNAO) has unanimously endorsed a position statement, which raises serious questions about the level of education and regulatory oversight physician assistants have and how these could jeopardize patients..."
abstract: Association of Skeletal Muscle Wasting With Treatment With Sorafenib
Note: this study is not specific to ovarian cancer but may be of interest for those deciding on Sorafenib:
Risk factors for reproductive and breast cancers among older lesbians.
Note: the term 'older' in the study was >40 yrs
Cochrane Collaboration review: Antigen-specific active immunotherapy for ovarian cancer
"AUTHORS' CONCLUSIONS: We conclude that despite promising immunological responses no clinically effective antigen-specific active immunotherapy is yet available for ovarian cancer. Furthermore, the adoption of guidelines to ensure uniformity in trial conduct, response definitions and trial reporting is recommended to improve quality and comparability of immunotherapy trials."
Cochrane Collaboration Review: Management of drainage for malignant ascites in gynecologic cancer
"AUTHORS' CONCLUSIONS: Since no relevant studies were identified, we are unable to make recommendations regarding the management of drains for malignant ascites in women with gynaecological cancer. Large, multi-centre RCTs are required to evaluate the efficacy and safety of the management of ascitic drains when in situ and their impact on QOL."
Analysis of Marshall Edwards, Inc.'s OVATURE Trial to Proceed Following Database Lock
"The OVATURE trial is a major multi-center international Phase III clinical trial of orally-administered investigational drug phenoxodiol in combination with carboplatin in women with advanced ovarian cancer resistant or refractory to platinum-based drugs, to determine its safety and effectiveness when used in combination with carboplatin.......The Company expects the final analysis will be performed strictly according to the protocol and now is expected to be completed in the second quarter of 2010"
Search of: Open Studies | Interventional Studies | ovarian cancer | Adult | received from 01/01/2010 to 01/22/2010
Results = 3 (new interventional studies since Jan 1/10)
Subscribe to:
Posts
(
Atom
)
